Compare PAHC & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAHC | DRTS |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2014 | 2021 |
| Metric | PAHC | DRTS |
|---|---|---|
| Price | $37.88 | $14.27 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $44.00 | $17.80 |
| AVG Volume (30 Days) | 192.2K | ★ 437.4K |
| Earning Date | 11-04-2026 | 11-19-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | ★ 104.20 | N/A |
| EPS | ★ 2.43 | N/A |
| Revenue | ★ $833,350,000.00 | N/A |
| Revenue This Year | $3.83 | N/A |
| Revenue Next Year | $3.49 | $1,235.59 |
| P/E Ratio | $15.06 | ★ N/A |
| Revenue Growth | ★ 4.12 | N/A |
| 52 Week Low | $28.25 | $3.43 |
| 52 Week High | $60.08 | $15.79 |
| Indicator | PAHC | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 61.25 | 46.09 |
| Support Level | $36.47 | $13.73 |
| Resistance Level | $37.92 | $15.01 |
| Average True Range (ATR) | 1.27 | 0.57 |
| MACD | 0.27 | -0.12 |
| Stochastic Oscillator | 92.90 | 11.24 |
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.